Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleA new AI-driven vaccine technology has been developed, aiming to provide broad immunity against entire families of viruses and future mutations with a single injection. Researchers believe this “super-antigen” approach, created using AI machine learning, could prevent future pandemics, save millions of lives and eliminate the need for lockdowns. A world-first Phase I human trial of a universal Sarbeco coronavirus vaccine, developed by the University of Cambridge and DIOSynVax, demonstrated its safety and triggered an immune response against SARS-CoV-2, SARS, and related bat viruses. The vaccine is administered using a needle-free microfluid jet, which delivers vaccine blueprints directly into skin cells. Experts, including Professor Jonathan Heeney and Professor Saul Faust, hail this as a “big paradigm change” from current reactive vaccine development, offering “future-proofed” protection against emerging pathogens. In fullAI ‘super-antigen’ vaccine could protect against whole families of virusesThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
Scientists develop vaccine using AI that could prevent future pandemics
Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleA new AI-driven vaccine technology has been developed, aiming to provide broad immunity against entire families of viruses and future mutations with a single injection. Researchers believe this “super-antigen” approach, created using AI machine learning, could prevent future pandemics, save millions of lives and eliminate the need for lockdowns. A world-first Phase I human trial of a universal Sarbeco coronavirus vaccine, developed by the University of Cambridge and DIOSynVax, demonstrated its safety and triggered an immune response against SARS-CoV-2, SARS, and related bat viruses. The vaccine is administered using a needle-free microfluid jet, which delivers vaccine blueprints directly into skin cells. Experts, including Professor Jonathan Heeney and Professor Saul Faust, hail this as a “big paradigm change” from current reactive vaccine development, offering “future-proofed” protection against emerging pathogens. In fullAI ‘super-antigen’ vaccine could protect against whole families of virusesThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
